Allogeneic peripheral blood hematopoietic stem cell transplantation for patients with hematologic malignancies

Abstract

To investigate the therapeutic effects and associated complications of allogeneic peripheral blood stem cell transplantation (allo-PBSCT). 10 patients with various malignant hematopoietic diseases received allo PBSCT. The preparative regimens were based on BUCY2 or modified BUCY2. The acute graft versus host disease (aGVIII) was prevented by cyclosporin A and shortterm MTX regimen in all patients. Two patients from donors with one fully mismatched HLA on DRB1 locus and 4 from unrelated donor also administered Zenapox (CD25 MAb) at dosage of 1 mg/kg every day on the day before transplantation and day 1 after transplantation. These 6 patients were also treated with mycophenolate mofetil (MMF). Transfusion of the donor cells: The median of the transfused nucleated cells was 5.38<10⁸/kg and that of the CD34′ cells was 7.8×10⁶/kg respectively. All the patients gained hematopoietic reconstruction except one who died of infection before engraftment. Seven patients got II′ IV^o aGVHD, and the incidence was 17.5%. Fourteen patients got cGVHD and the incidence was 53.8% in the patients who survived over 6 months. Twenty-eight patients had fever or other characteristics of infection. The median follow-up time was 13.8 months. The incidence of transplantation related mortality (TRM) was 17.5% and 2 patients relapsed (5.0_). It was concluded that allo PBSCT can reconstruct hematopoiesis quickly and is a favorable therapeutic method for leukemia.

Keywords

leukemia / peripheral blood stem cell transplantation, allogeneic / graft-vesus-host disease